| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
189,404 |
399,536 |
1,290,262 |
1,508,328 |
| Total Sell Value |
$12,345,106 |
$25,699,014 |
$76,337,922 |
$84,710,991 |
| Total People Sold |
8 |
10 |
12 |
12 |
| Total Sell Transactions |
20 |
40 |
91 |
94 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Przybyl Arthur |
President and CEO |
• • – |
2013-10-09 |
4 |
A |
$0.00 |
$0 |
D/D |
12,139 |
51,109 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-10-09 |
4 |
D |
$9.93 |
$13,550 |
D/D |
(1,364) |
16,177 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-10-09 |
4 |
A |
$0.00 |
$0 |
D/D |
3,675 |
17,541 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-10-02 |
4 |
D |
$10.09 |
$13,768 |
D/D |
(1,364) |
13,866 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,675 |
15,230 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-10-02 |
4 |
D |
$10.10 |
$56,984 |
D/D |
(5,644) |
38,970 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,139 |
44,614 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-09-25 |
4 |
D |
$9.09 |
$51,284 |
D/D |
(5,644) |
32,475 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-09-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,139 |
38,119 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-09-25 |
4 |
D |
$9.11 |
$12,421 |
D/D |
(1,364) |
11,555 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-09-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,675 |
12,919 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-09-18 |
4 |
D |
$8.18 |
$11,160 |
D/D |
(1,364) |
9,244 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
3,675 |
10,608 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-09-18 |
4 |
D |
$8.19 |
$46,216 |
D/D |
(5,644) |
25,980 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
12,139 |
31,624 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-09-11 |
4 |
D |
$6.97 |
$9,501 |
D/D |
(1,364) |
6,933 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,675 |
8,297 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-09-11 |
4 |
D |
$6.97 |
$39,317 |
D/D |
(5,644) |
19,485 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
12,139 |
25,129 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-09-04 |
4 |
D |
$6.95 |
$39,234 |
D/D |
(5,644) |
12,990 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-09-04 |
4 |
A |
$0.00 |
$0 |
D/D |
12,139 |
18,634 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-09-04 |
4 |
D |
$6.96 |
$9,488 |
D/D |
(1,364) |
4,622 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-09-04 |
4 |
A |
$0.00 |
$0 |
D/D |
3,675 |
5,986 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-08-28 |
4 |
D |
$7.07 |
$39,875 |
D/D |
(5,644) |
6,495 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-08-28 |
4 |
A |
$0.00 |
$0 |
D/D |
12 |
12 |
|
- |
|
725 Records found
|
|
Page 22 of 29 |
|
|
0.14 (0.21%) 
